Wells Fargo Lifts Regeneron Target to $800, Cites Extended Dupixent Exclusivity
Wells Fargo increased its price target for Regeneron Pharmaceuticals to $800 from $745 while retaining an Equal Weight rating. The firm based the revision on a more optimistic timeline for Dupixent patent protection and modeled stronger earnings and profit share for the drug, even as it remains cautious about Regeneron’s LAG3 program and awaits mul…